Rehmapicroside |
| Catalog No.GC60319 |
Rehmapicroside is an ionone glycoside isolated from the rhizome of Rehmannia glutinosa, which has antitumor, antioxidant, anti-inflammatory and neuroprotective activities.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 104056-82-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Rehmapicroside is an ionone glycoside isolated from the rhizome of Rehmannia glutinosa, which has antitumor, antioxidant, anti-inflammatory and neuroprotective activities[1, 2, 3].
In vitro, Rehmapicroside (0-100μM) treatment of hepatocellular carcinoma (HCC) cell lines (HepG2, SNU-739 cells) for 24h inhibited cell proliferation in a dose-dependent manner, inhibited cell migration and invasion, induced cell G2/M phase arrest, and had no toxicity to normal cells[4]. Rehmapicroside (12.5-100μM) treatment of PC12 cells cultured under oxygen-glucose deprivation and reoxygenation (OGD/RO) conditions for 24h increased cell viability in a dose-dependent manner, reduced intracellular O2− and ONOO−, upregulated the expression of Bcl-2 but downregulated the expression of Bax and Caspase-3, and reduced the ratio of LC3-II to LC3-I[5].
In vivo, Rehmapicroside (10mg/kg) was intraperitoneally injected into rats that underwent middle cerebral artery occlusion (MCAO) surgery, which reduced the area of cerebral infarction, improved the neurological deficit score, and inhibited the formation of 3-nitrotyrosine, Drp1 nitration, and the expression of NADPH oxidase and iNOS in the rat brain tissue[5].
References:
[1] Anh N T H, Sung T V, Franke K, et al. Phytochemical studies of Rehmannia glutinosa rhizomes[J]. Die Pharmazie-An International Journal of Pharmaceutical Sciences, 2003, 58(8): 593-595.
[2] Zhao L, Cai R. Cracking the Bioactive Code of Rehmannia glutinosa: Analysis and Functions of Active Components[J]. Biological Evidence, 2024, 14.
[3] Zhang R X, Li M X, Jia Z P. Rehmannia glutinosa: review of botany, chemistry and pharmacology[J]. Journal of ethnopharmacology, 2008, 117(2): 199-214.
[4] Zhao X, Bai Z, Song Y. Targeting suppression of AKT activation boosts chemosensitivity of hepatocarcinoma cells via regulation of inflammation and metastasis: Functional protection of Rehmapicroside[J]. Journal of Functional Foods, 2024, 122: 106487.
[5] Zhang Y, He Y, Wu M, et al. Rehmapicroside ameliorates cerebral ischemia-reperfusion injury via attenuating peroxynitrite-mediated mitophagy activation[J]. Free Radical Biology and Medicine, 2020, 160: 526-539.
| Cell experiment [1]: | |
Cell lines | HepG2、SNU-739 cells |
Preparation Method | HepG2 and SNU-739 cells were incubated with 0-100μM Rehmapicroside, cisplatin (cDDP) alone, or the two in combination at the indicated concentrations for 24h. Then, all cells were collected for cell viability calculation using CCK-8 analysis. |
Reaction Conditions | 0-100μM; 24h |
Applications | Rehmapicroside inhibits the proliferation of Hepatocellular carcinoma (HCC) cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Sprague-Dawley (SD) rats |
Preparation Method | Experimental Groups and Drug TreatmentRats were randomly divided into following groups including sham control, shamcontrol plus Rehmapicroside (10mg/kg), middle cerebral artery occlusion (MCAO), MCAO plus Rehmapicroside (2.5, 5, 10mg/kg wt) and MCAO plus FeTMPyP (peroxynitrite decomposition catalyst, PDC) (3mg/kg). Rehmapicroside was injected into the peritoneum at the beginning of reperfusion after 2h of MCAO ischemia. FeTMPyP (3mg/kg wt) was used as positivecontrol. Both Rehmapicroside and PDC dissolved in saline at designed dosages wereintraperitoneally administrated into the rats at the onset of reperfusion. The volumefor the injection treatment was 5mL/kg. In a parallel experiment, the same volume of saline was used as a control. |
Dosage form | 2.5, 5, 10mg/kg; i.p. |
Applications | Rehmapicroside alleviates mitophagy activation and apoptosis in MCAO ischemia-reperfused rats. Rehmapicroside suppresses 3-nitrotyrosine formation, Drp1 nitration as well as NADPH oxidases and iNOS expression in MCAO ischemia-reperfused rat brains. |
References: | |
| Cas No. | 104056-82-8 | SDF | |
| Canonical SMILES | CC([C@]1([H])O[C@@H]2O[C@@H]([C@@H](O)[C@H](O)[C@H]2O)CO)=C(C(C)(C)CC1)C(O)=O | ||
| Formula | C16H26O8 | M.Wt | 346.37 |
| Solubility | Storage | Store at 2-8°C,protect from light | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.8871 mL | 14.4354 mL | 28.8709 mL |
| 5 mM | 577.4 μL | 2.8871 mL | 5.7742 mL |
| 10 mM | 288.7 μL | 1.4435 mL | 2.8871 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 38 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *